Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listDEFEROXAMINE MESYLATE

DEFEROXAMINE MESYLATE

Synonym(s):Deferoxamine mesylate salt;DFOM;Deferoxamine methanesulfonate salt;Desferrioxamine mesylate salt;Desferrioxamine Mesylate, DFOM, Iron Chelator II

  • CAS NO.:138-14-7
  • Empirical Formula: C26H52N6O11S
  • Molecular Weight: 656.79
  • MDL number: MFCD00058605
  • EINECS: 205-314-3
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-04-24 17:21:45
DEFEROXAMINE MESYLATE Structural

What is DEFEROXAMINE MESYLATE?

Description

Deferoxamine is a bacterial siderophore that chelates iron. It is used to experimentally inhibit iron-dependent prolyl hydroxylases (EC50 = 17.8 μM), thus preventing the degradation of isoforms of hypoxia inducible factor during normoxia. Deferoxamine has applications in diseases that are characterized by high levels of circulating iron, such as thalassemia major.

Chemical properties

DEFEROXAMINE MESYLATE is white or almost white powder.

The Uses of DEFEROXAMINE MESYLATE

DEFEROXAMINE MESYLATE is an iron chelating agent used in therapy for patients with sickle cell diseases and iron overload. Studies suggest that it can exert potential antioxidant neuroprotective effects in stroke patients

The Uses of DEFEROXAMINE MESYLATE

chelating agent (Fe & Al)

What are the applications of Application

Deferoxamine mesylate is a bacterial siderophore, an iron chelator which induces apoptosis and is used to experimentally inhibit iron-dependent prolyl hydoxylases.

brand name

Desferal (Novartis).

Biochem/physiol Actions

An iron chelator used often in the studies of cell proliferation and apoptosis. Has been shown to have anti-proliferative effects on vascular smooth muscle cells in vitro and in vivo and to arrest cells in the G1 phase. Also reported to induce p53. Induces apoptosis in HL-60 cells by chelating iron. After 48 hrs treatment with 1μM deferoxamine, DNA fragmentation was apparent. Cells treated with 0.1 μM deferoxamine for as little as 24 hours were committed to apoptosis; by 48 hrs nuclear collapse was observed. In some studies it has been shown to have antioxidant properties and to protect cells against H2O2-induced damage.

Clinical Use

Chelating agent:
Acute iron poisoning
Chronic iron or aluminium overload

Veterinary Drugs and Treatments

Deferoxamine is used for the treatment of either acute or chronic iron toxicity. It is being evaluated as an iron chelator for adjunctive treatment of acute cardiac ischemia and as a chelator for aluminum toxicity. Its efficacy in treating reperfusion injuries has been disappointing.

Drug interactions

Potentially hazardous interactions with other drugs
Avoid prochlorperazine, levomepromazine and methotrimeprazine (prolonged unconsciousness).
Do not administer with blood.

Metabolism

When given parenterally desferrioxamine forms chelates with iron and aluminium ions to form ferrioxamine and aluminoxamine, respectively. The chelates are excreted in the urine and faeces via the bile. Desferrioxamine is metabolised, mainly in the plasma. Four metabolites of desferrioxamine were isolated from urine of patients with iron overload. The following biotransformation reactions were found to occur with desferrioxamine: transamination and oxidation yielding an acid metabolite, beta-oxidation also yielding an acid metabolite, decarboxylation and N-hydroxylation yielding neutral metabolites.

storage

Store at -20°C

Properties of DEFEROXAMINE MESYLATE

Melting point: 148-149°
storage temp.  2-8°C
solubility  H2O: 50 mg/mL
form  powder
color  white to off-white
Water Solubility  Soluble to 100 mM in water

Safety information for DEFEROXAMINE MESYLATE

Signal word Warning
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
GHS Hazard Statements H315:Skin corrosion/irritation
H319:Serious eye damage/eye irritation
Precautionary Statement Codes P280:Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352:IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P332+P313:IF SKIN irritation occurs: Get medical advice/attention.
P337+P313:IF eye irritation persists: Get medical advice/attention.

Computed Descriptors for DEFEROXAMINE MESYLATE

Related products of tetrahydrofuran

You may like

  • 138-14-7 Deferoxamine mesylate USP/Ph. Eur 99%
    138-14-7 Deferoxamine mesylate USP/Ph. Eur 99%
    138-14-7
    View Details
  • Desferrioxamine mesylate 98%
    Desferrioxamine mesylate 98%
    138-14-7
    View Details
  • Deferoxamine mesylate CAS 138-14-7
    Deferoxamine mesylate CAS 138-14-7
    138-14-7
    View Details
  • Deferoxamine mesylate salt powder, ≥92.5% (TLC) CAS 138-14-7
    Deferoxamine mesylate salt powder, ≥92.5% (TLC) CAS 138-14-7
    138-14-7
    View Details
  • Deferoxamine mesylate CAS 138-14-7
    Deferoxamine mesylate CAS 138-14-7
    138-14-7
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.